This Article Full Text Full Text (PDF) All Versions of this Article: 38/7/2038    most recent STROKEAHA.107.487124v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mattle, H. P. Search for Related Content PubMed PubMed Citation Articles by Mattle, H. P. Pubmed/NCBI databases Substance via MeSH Hazardous Substances DB HEPARIN Medline Plus Health Information Stroke Related Collections Emergency treatment of Stroke Thrombolysis Related Article

(Stroke. 2007;38:2038.)
© 2007 American Heart Association, Inc.

Editorials

Intravenous or Intra-Arterial Thrombolysis?

It’s Time to Find the Right Approach for the Right Patient

Heinrich P. Mattle

From Department of Neurology, Inselspital, University of Berne, Switzerland.

Key Words: rt-PA • stroke

An extract of the first 250 words of the full text is provided, because this article has no abstract.

See related article, pages 2191–2195.

Intravenous recombinant tissue plasminogen activator (rt-PA) given within 3 hours of stroke onset is considered the standard treatment of stroke and is approved by the health authorities of most countries. It increases the rate of favorable outcomes from the range of 20% to 38% to 31% to 50%.¹ Patients with mild or moderate strokes, persons younger than 75 years, and patients treated very early have the best chance for a favorable outcome to treatment.^2,3 Nevertheless, more than half of stroke victims face a bleak outlook. Therefore, better means to treat stroke are needed. Intra-arterial thrombolysis (IAT) with pro-urokinase and a small dose of heparin has been tested in a phase III trial to treat stroke patients of <6 hours duration because of middle cerebral artery (MCA) main stem (M1 segment) and main branch (M2 segment) occlusion.⁴ Recanalization rates were 66% when treated with pro-urokinase and 18% with placebo (P<0.001). At 90 days, 40% of patients treated with pro-urokinase but only 25% assigned to placebo had regained independency (modified Rankin scale of 0, 1, or 2; P=0.04).

The FDA has not approved pro-urokinase for stroke treatment. Nevertheless, IAT mostly with rt-PA or urokinase is used increasingly at stroke centers by interventionalists. Since the FDA granted approval of the MERCI retriever for arterial embolectomy, mechanical recanalization has gained popularity as well.⁵ Forty-five percent of occluded MCAs and 53% of occluded intracranial internal carotid arteries were recanalized successfully with the MERCI retriever. Vessel recanalization . . . [Full Text of this Article]

Related Article:

Debunking 7 Myths That Hamper the Realization of Randomized Controlled Trials on Intra-Arterial Thrombolysis for Acute Ischemic Stroke

Alfonso Ciccone, Luca Valvassori, Roberto Gasparotti, Francesco Scomazzoni, Elena Ballabio, and Roberto Sterzi
Stroke 2007 38: 2191-2195. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

				M. B. Maas, K. L. Furie, M. H. Lev, H. Ay, A. B. Singhal, D. M. Greer, G. J. Harris, E. Halpern, W. J. Koroshetz, and W. S. Smith National Institutes of Health Stroke Scale Score Is Poorly Predictive of Proximal Occlusion in Acute Cerebral Ischemia Stroke, September 1, 2009; 40(9): 2988 - 2993. [Abstract] [Full Text] [PDF]

				V. Puetz, I. Dzialowski, S. B. Coutts, M. D. Hill, A. Krol, C. O'Reilly, M. Goyal, A. M. Demchuk, and for the Calgary CTA Study Group Frequency and Clinical Course of Stroke and Transient Ischemic Attack Patients With Intracranial Nonocclusive Thrombus on Computed Tomographic Angiography Stroke, January 1, 2009; 40(1): 193 - 199. [Abstract] [Full Text] [PDF]

				C. Nichols, P. Khatri, T. Tomsick, and J. Broderick Advantages of a Combined Approach to Recanalization Therapy Stroke, April 1, 2008; 39(4): e71 - e71. [Full Text] [PDF]